



"C'mon, c'mon-it's either one or the other."

NCATS: NIH Center for Advancing Translational Sciences, Overview

Noel Southall, PhD Informatics, NIH/NCATS February 4, 2013



NCATS Mission



To catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions.



Characteristics of NCATS Initiatives and Programs

- Address significant bottlenecks in the process of translation
- Highly collaborative across NIH, other government agencies, and with the private sector.
- Quick to respond to needs of biomedical researchers




NCATS Informatics

- Experimental design, data analysis and software development in support of research projects:
 - » Laboratory information management
 - » High-throughput screening data analysis
 - » RNAi screening data analysis
 - » Bioinformatics support
 - » Ligand-based modeling support
 - » Structure-based modeling support
 - » Statistics support
 - » Web application development
 - » Computational tool development



tripod.nih.gov




NCATS' Therapeutics for Rare and Neglected Diseases (TRND)

- Preclinical development expertise applied to rare disease programs
- To what extent should NCATS' portfolio invest in drug repurposing approaches for rare diseases?
 - » How successful had it been historically?
 - » Were there existing programs that were stalled?
 - » Best methods for generating repurposing leads?
- Collaborate with FDA/OOPD Office of Orphan Products Development
 - » Rare disease repurposing database (RDRD)
 - » Orphan product designation coupled to UNII generation



FDA Substance Registration System

Food and Drug Administration Substance Registration System Standard Operating Procedure





NCATS' Therapeutics for Rare and Neglected Diseases (TRND)

Drug registration information informing program policy, strategy

- How successful had it been historically?
 - » Surprisingly successful (e.g. CF)
 - » Not always straight-forward (lenalidomide)
- Were there existing programs that were stalled?
 - » Generally not for business reasons
- Best methods for generating repurposing leads?
 - » Random screening approaches complement directed ones
- How to build a physical library for repurposing screens?



How Many Drugs Are There?

		Term			FDA	Wo	orld	wid	e /	
	Tylenol 8 Hour, Dayquil Sinus IyQuil Cough, Infants' Tylenol			>	140,000					Product with defined package ze, dose, formulation of API(s)
	Tylenol, Acetominophen, Panadol, Datril, Paracetamol	Drug		>	19,000	>25	>25,000		Brand or generic name of approved product that defines API(s)	
	103-90-2		API		4,695	7,9	7,980		Physical substance intended to be used in manufacture of drug product	
	HO		Active Moiety		2,794	4,37	74			al moiety excluding salts, esters, etc. ble for pharmacological activity
			HTS Suitab	1	1,817	2,75				entity of defined structure o high-throughput screening
US FDBritaiEMA	natics sources for NPC PA: Orange Book, OTC, NDC, Green E Drugs@FDA n NHS h Canada	Book,						Phy	ysic - -	ral sources for NPC Procurement from >70 suppliers worldwide In-house purification of APIs from marketed forms Custom synthesis

National Center

Registration of Substances and Related Information Based on ISO 11238

Scope

This International Standard provides an information model to define and identify substances within medicinal products or substances used for medicinal purposes, including dietary supplements, foods and cosmetics.

INTERNATIONAL STANDARD

ISO 11238

First edition 2012-xx-xx

Health informatics — Identification of medicinal products — Data elements and structures for the unique identification and exchange of regulated information on substances

Informatique de santé — Identification des médicaments — Éléments de données et structures pour l'identification unique et l'échange d'informations réglementées concernant les substances





Reference number ISO 11238:2012(E)

A Path to ISO 11238 Implementation

- FDA/OC considering update of SRS to ISO 11238 standard
- NCATS motivated by interest, experience and aligned mission
- HHS Interagency Research Collaboration
 Agreement to structure the collaboration



ISO 11238 Implementation

- Enable the deposition of new substances and relationships between substances
- Adhere to the ISO standard for each type, grouping of substance
- Provide a reference for every annotation within the system
- Publish/distribute public information on substance registrations
- Cooperate on depositing substances into a 'master' system that can issue ISO IDs



Man v Software; e.g. Uniqueness

- The system must support the adjudication of substance records by a regulatory authority, not automate or replace that adjudication
 - The capture of specified substances must satisfy existing regulations; e.g. EMA SPC and USC/CFR
 - » Be responsive to the needs of product sponsors and the innovation presented by new products
- Where possible, that framework ('business rules') should be tested algorithmically during substance entry to ensure consistency across registrations
 - » Ultimate responsibility rests with a registrar, however
 - » Relevant (defining) aspects of that decision should be captured



Meeting Goals

- Encourage international cooperation on the implementation of ISO 11238
- Discuss the practicalities of implementing the standard for each of the different types of specified substances
- Identify additional functional requirements for an implementation system

